Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daprodustat vs rhEPO on Iron Absorption in CKD Anemia
NCT03457701Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daprodustat in anemia of chronic kidney disease (CKD-A) (4 arms), sponsored by GSK. Primary endpoint: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO at Day 57. Started Jul 2019; status: completed.
02
Drugs
daprodustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03457701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457701.